{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:15:56Z","timestamp":1778228156047,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-021-00613-9","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T21:02:40Z","timestamp":1614805360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia"],"prefix":"10.1007","author":[{"given":"Anthony","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"issue":"3","key":"613_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjh.12756","volume":"165","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014;165(3):273\u201386. https:\/\/doi.org\/10.1111\/bjh.12756.","journal-title":"Br J Haematol"},{"issue":"20","key":"613_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood."},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"\u2022 Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333. https:\/\/doi.org\/10.1038\/bcj.2015.53Large, collaborative study comparing the performance of 7 prognostic models in CMML as well as the impact of several gene mutations.","journal-title":"Blood Cancer J"},{"issue":"3","key":"613_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383. https:\/\/doi.org\/10.3324\/haematol.2010.030957.","journal-title":"Haematologica."},{"issue":"12","key":"613_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135. https:\/\/doi.org\/10.1002\/ajh.23846.","journal-title":"Am J Hematol"},{"issue":"2","key":"613_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1046\/j.1365-2141.2000.01868.x","volume":"108","author":"F Sole","year":"2000","unstructured":"Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol. 2000;108(2):346\u201356. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01868.x.","journal-title":"Br J Haematol"},{"issue":"10","key":"613_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"\u2022\u2022 Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317. https:\/\/doi.org\/10.1182\/blood-2016-05-714030The CPSS-mol model represents the most recently created and most genomically comprehensive prognostic model in CMML.","journal-title":"Blood"},{"issue":"22","key":"613_CR8","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327; quiz 99. https:\/\/doi.org\/10.1182\/blood-2013-08-518886.","journal-title":"Blood."},{"issue":"15","key":"613_CR9","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","volume":"120","author":"M Meggendorfer","year":"2012","unstructured":"Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080\u20138. https:\/\/doi.org\/10.1182\/blood-2012-01-404863.","journal-title":"Blood."},{"issue":"19","key":"613_CR10","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"\u2022\u2022 Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428\u201336. https:\/\/doi.org\/10.1200\/JCO.2012.47.3314The GFM model is one of three molecularly-inspired prognostic models in CMML and evaluates phenotpyic and prognostic relevance of a number of gene mutations.","journal-title":"J Clin Oncol"},{"issue":"11","key":"613_CR11","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"\u2022\u2022 Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206\u201312. https:\/\/doi.org\/10.1038\/leu.2014.125The Mayo Molecular model is a clinico-genomic model that incorportes mutations in ASXL1. It is one of three such models currently in use in CMML prognostication.","journal-title":"Leukemia"},{"key":"613_CR12","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1038\/bcj.2015.9","volume":"5","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015;5:e280. https:\/\/doi.org\/10.1038\/bcj.2015.9.","journal-title":"Blood Cancer J"},{"issue":"10","key":"613_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ajh.24108","volume":"90","author":"G Tang","year":"2015","unstructured":"Tang G, Fu B, Hu S, Lu X, Tang Z, Li S, et al. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015;90(10):882\u20137. https:\/\/doi.org\/10.1002\/ajh.24108.","journal-title":"Am J Hematol"},{"issue":"8","key":"613_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ajh.23751","volume":"89","author":"G Tang","year":"2014","unstructured":"Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014;89(8):813\u20138. https:\/\/doi.org\/10.1002\/ajh.23751.","journal-title":"Am J Hematol"},{"issue":"9","key":"613_CR15","first-page":"1168","volume":"90","author":"F Sole","year":"2005","unstructured":"Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168\u201378.","journal-title":"Haematologica."},{"issue":"15","key":"613_CR16","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315. https:\/\/doi.org\/10.1182\/blood-2012-08-452938.","journal-title":"Blood."},{"key":"613_CR17","doi-asserted-by":"publisher","unstructured":"\u2022 Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34(5):1407-1421. doi:https:\/\/doi.org\/10.1038\/s41375-019-0690-7. Large collaborative study providing the most conclusive evidence to date in regard to the favorable prognostic relevance of TET2 mutations in CMML.","DOI":"10.1038\/s41375-019-0690-7"},{"key":"613_CR18","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1038\/bcj.2015.113","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385. https:\/\/doi.org\/10.1038\/bcj.2015.113.","journal-title":"Blood Cancer J"},{"issue":"24","key":"613_CR19","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","volume":"28","author":"A Kohlmann","year":"2010","unstructured":"Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858\u201365. https:\/\/doi.org\/10.1200\/JCO.2009.27.1361.","journal-title":"J Clin Oncol"},{"issue":"17","key":"613_CR20","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312. https:\/\/doi.org\/10.1182\/blood-2014-06-582809.","journal-title":"Blood."},{"issue":"23","key":"613_CR21","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"issue":"12","key":"613_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2011.39.2886","volume":"30","author":"VI Gaidzik","year":"2012","unstructured":"Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30(12):1350\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.39.2886.","journal-title":"J Clin Oncol"},{"issue":"35","key":"613_CR23","doi-asserted-by":"publisher","first-page":"14566","DOI":"10.1073\/pnas.1112317108","volume":"108","author":"M Ko","year":"2011","unstructured":"Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A. 2011;108(35):14566\u201371. https:\/\/doi.org\/10.1073\/pnas.1112317108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"613_CR24","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2010-12-324707","volume":"118","author":"E Pronier","year":"2011","unstructured":"Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A. da Costa Reis Monte Mor B et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011;118(9):2551\u20135. https:\/\/doi.org\/10.1182\/blood-2010-12-324707.","journal-title":"Blood."},{"issue":"12","key":"613_CR25","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","volume":"121","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12):2186\u201398. https:\/\/doi.org\/10.1182\/blood-2012-06-440347.","journal-title":"Blood."},{"issue":"2","key":"613_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4161\/epi.7.2.19015","volume":"7","author":"J Yamazaki","year":"2012","unstructured":"Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7(2):201\u20137. https:\/\/doi.org\/10.4161\/epi.7.2.19015.","journal-title":"Epigenetics."},{"issue":"3","key":"613_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/leu.2013.337","volume":"28","author":"E Solary","year":"2014","unstructured":"Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28(3):485\u201396. https:\/\/doi.org\/10.1038\/leu.2013.337.","journal-title":"Leukemia."},{"issue":"7325","key":"613_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839\u201343. https:\/\/doi.org\/10.1038\/nature09586.","journal-title":"Nature."},{"issue":"1","key":"613_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.24581","volume":"92","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92(1):56\u201361. https:\/\/doi.org\/10.1002\/ajh.24581.","journal-title":"Am J Hematol"},{"issue":"14","key":"613_CR30","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932\u201341. https:\/\/doi.org\/10.1182\/blood-2010-10-311019.","journal-title":"Blood."},{"issue":"4","key":"613_CR31","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/leu.2015.211","volume":"30","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30(4):980\u20134. https:\/\/doi.org\/10.1038\/leu.2015.211.","journal-title":"Leukemia."},{"issue":"3","key":"613_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.23373","volume":"88","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88(3):201\u20136. https:\/\/doi.org\/10.1002\/ajh.23373.","journal-title":"Am J Hematol"},{"issue":"7367","key":"613_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139. https:\/\/doi.org\/10.1038\/nature10496.","journal-title":"Nature."},{"issue":"22","key":"613_CR34","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood.V128.22.4337.4337","volume":"128","author":"G Todisco","year":"2016","unstructured":"Todisco G, Gall\u00ec A, Travaglino E, Rizzo E, Molteni E, Elena C, et al. SRSF2 Mutations identify a distinct subtype of myeloid neoplasm across myelodysplastic syndromes and acute myeloid leukemia. Blood. 2016;128(22):4337. https:\/\/doi.org\/10.1182\/blood.V128.22.4337.4337.","journal-title":"Blood"},{"issue":"9","key":"613_CR35","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","volume":"124","author":"L Malcovati","year":"2014","unstructured":"Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513\u201321. https:\/\/doi.org\/10.1182\/blood-2014-03-560227.","journal-title":"Blood."},{"issue":"12","key":"613_CR36","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","volume":"99","author":"M Meggendorfer","year":"2014","unstructured":"Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):e244\u20136. https:\/\/doi.org\/10.3324\/haematol.2014.113159.","journal-title":"Haematologica."},{"issue":"7","key":"613_CR37","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310. https:\/\/doi.org\/10.1038\/leu.2013.88.","journal-title":"Leukemia."},{"issue":"2","key":"613_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180\u201393. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.032.","journal-title":"Cancer Cell"},{"issue":"7","key":"613_CR39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2011.58","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25(7):1200\u20132. https:\/\/doi.org\/10.1038\/leu.2011.58.","journal-title":"Leukemia."},{"issue":"3","key":"613_CR40","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.beha.2020.101195","volume":"33","author":"AM Hunter","year":"2020","unstructured":"Hunter AM, Padron E. Molecular genetics of MDS\/MPN overlap syndromes. Best Pract Res Clin Haematol. 2020;33(3):101195. https:\/\/doi.org\/10.1016\/j.beha.2020.101195.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"613_CR41","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","volume":"16","author":"C Ricci","year":"2010","unstructured":"Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16(8):2246\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2112.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"613_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","volume":"151","author":"V Gelsi-Boyer","year":"2010","unstructured":"Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08381.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"613_CR43","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.23702","volume":"89","author":"N Cervera","year":"2014","unstructured":"Cervera N, Itzykson R, Coppin E, Prebet T, Murati A, Legall S, et al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. Am J Hematol. 2014;89(6):604\u20139. https:\/\/doi.org\/10.1002\/ajh.23702.","journal-title":"Am J Hematol"},{"issue":"9","key":"613_CR44","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jcp.2009.065904","volume":"62","author":"A Pich","year":"2009","unstructured":"Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62(9):798\u2013801. https:\/\/doi.org\/10.1136\/jcp.2009.065904.","journal-title":"J Clin Pathol"},{"issue":"6","key":"613_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","volume":"42","author":"HD Gur","year":"2018","unstructured":"Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, et al. Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018;42(6):799\u2013806. https:\/\/doi.org\/10.1097\/PAS.0000000000001058.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"613_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cam4.1946","volume":"8","author":"M Faisal","year":"2019","unstructured":"Faisal M, Stark H, Busche G, Schlue J, Teiken K, Kreipe HH, et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med. 2019;8(2):742\u201350. https:\/\/doi.org\/10.1002\/cam4.1946.","journal-title":"Cancer Med"},{"issue":"1","key":"613_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.23345","volume":"88","author":"N Daver","year":"2013","unstructured":"Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88(1):56\u20139. https:\/\/doi.org\/10.1002\/ajh.23345.","journal-title":"Am J Hematol"},{"issue":"19","key":"613_CR48","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1214514.","journal-title":"N Engl J Med"},{"key":"613_CR49","doi-asserted-by":"crossref","unstructured":"Anthony M. Hunter RN, Mohammad Hussaini, Ratilal Akabari, Alan F. List, Jeffrey Lancet, David A. Sallman, Rami S. Komrokji, Javier Pinilla Ibarz, Andrew T Kuykendall, Ling Zhang, Eric Padron. CSF3R mutations are exceedingly rare genetic events assicated with inferior survival and sensitivity to ruxolitinib across myeloid malignancies. Blood. 2019.","DOI":"10.1182\/blood-2019-130196"},{"issue":"5","key":"613_CR50","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/path.2677","volume":"220","author":"K Sotlar","year":"2010","unstructured":"Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220(5):586\u201395. https:\/\/doi.org\/10.1002\/path.2677.","journal-title":"J Pathol"},{"issue":"10","key":"613_CR51","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","volume":"104","author":"P Valent","year":"2019","unstructured":"\u2022 Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104(10):1935\u201349. https:\/\/doi.org\/10.3324\/haematol.2019.222059Recent international consesus recommendations on diagnosif of CMML and CMML variants.","journal-title":"Haematologica"},{"issue":"15","key":"613_CR52","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","volume":"129","author":"R Sood","year":"2017","unstructured":"Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129(15):2070\u201382. https:\/\/doi.org\/10.1182\/blood-2016-10-687830.","journal-title":"Blood."},{"issue":"8","key":"613_CR53","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/leu.2009.48","volume":"23","author":"MC Kuo","year":"2009","unstructured":"Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23(8):1426\u201331. https:\/\/doi.org\/10.1038\/leu.2009.48.","journal-title":"Leukemia."},{"issue":"15","key":"613_CR54","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-14-2203","volume":"21","author":"SC Tsai","year":"2015","unstructured":"Tsai SC, Shih LY, Liang ST, Huang YJ, Kuo MC, Huang CF, et al. Biological activities of runx1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic syndromes. Clin Cancer Res. 2015;21(15):3541\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2203.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"613_CR55","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","volume":"95","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase A, Zoi K, Waghorn K, Hidalgo-Curtis C, Score J, et al. Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2010;95(9):1473\u201380. https:\/\/doi.org\/10.3324\/haematol.2010.021808.","journal-title":"Haematologica."},{"issue":"23","key":"613_CR56","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1182\/blood-2014-03-562637","volume":"123","author":"E Padron","year":"2014","unstructured":"Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, et al. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014;123(23):3675\u20137. https:\/\/doi.org\/10.1182\/blood-2014-03-562637.","journal-title":"Blood."},{"issue":"8","key":"613_CR57","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ng.2696","volume":"45","author":"H Makishima","year":"2013","unstructured":"Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942\u20136. https:\/\/doi.org\/10.1038\/ng.2696.","journal-title":"Nat Genet"},{"issue":"6","key":"613_CR58","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/leu.2013.35","volume":"27","author":"F Damm","year":"2013","unstructured":"Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013;27(6):1401\u20133. https:\/\/doi.org\/10.1038\/leu.2013.35.","journal-title":"Leukemia."},{"issue":"1","key":"613_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18\u201324. https:\/\/doi.org\/10.1038\/ng.2495.","journal-title":"Nat Genet"},{"key":"613_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1146\/annurev-genet-102108-134233","volume":"43","author":"K Nasmyth","year":"2009","unstructured":"Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet. 2009;43:525\u201358. https:\/\/doi.org\/10.1146\/annurev-genet-102108-134233.","journal-title":"Annu Rev Genet"},{"issue":"7180","key":"613_CR61","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nature06634","volume":"451","author":"KS Wendt","year":"2008","unstructured":"Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, Schirghuber E, et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature. 2008;451(7180):796\u2013801. https:\/\/doi.org\/10.1038\/nature06634.","journal-title":"Nature."},{"issue":"10","key":"613_CR62","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/ng.2731","volume":"45","author":"A Kon","year":"2013","unstructured":"Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45(10):1232\u20137. https:\/\/doi.org\/10.1038\/ng.2731.","journal-title":"Nat Genet"},{"issue":"11","key":"613_CR63","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","volume":"124","author":"S Thota","year":"2014","unstructured":"Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014;124(11):1790\u20138. https:\/\/doi.org\/10.1182\/blood-2014-04-567057.","journal-title":"Blood."},{"issue":"1","key":"613_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajh.24939","volume":"93","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, et al. Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65\u201373. https:\/\/doi.org\/10.1002\/ajh.24939.","journal-title":"Am J Hematol"},{"issue":"26","key":"613_CR65","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1013343.","journal-title":"N Engl J Med"},{"issue":"12","key":"613_CR66","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41408-017-0004-0","volume":"7","author":"DA Sallman","year":"2017","unstructured":"Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, et al. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017;7(12):633. https:\/\/doi.org\/10.1038\/s41408-017-0004-0.","journal-title":"Blood Cancer J"},{"issue":"9","key":"613_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.82","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016;6(9):e472. https:\/\/doi.org\/10.1038\/bcj.2016.82.","journal-title":"Blood Cancer J"},{"key":"613_CR68","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","volume":"34","author":"G Coltro","year":"2019","unstructured":"Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2019;34:1407\u201321. https:\/\/doi.org\/10.1038\/s41375-019-0690-7.","journal-title":"Leukemia."},{"issue":"12","key":"613_CR69","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","volume":"97","author":"S Schnittger","year":"2012","unstructured":"Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative disorders: an analysis of 636 cases. Haematologica. 2012;97(12):1890\u20134. https:\/\/doi.org\/10.3324\/haematol.2012.065375.","journal-title":"Haematologica."},{"issue":"1","key":"613_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","volume":"8","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, et al. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J. 2018;8(1):12. https:\/\/doi.org\/10.1038\/s41408-017-0045-4.","journal-title":"Blood Cancer J"},{"issue":"12","key":"613_CR71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11864-018-0581-6","volume":"19","author":"AM Hunter","year":"2018","unstructured":"Hunter AM, Zhang L, Padron E. Current management and recent advances in the treatment of chronic myelomonocytic leukemia. Curr Treat Options in Oncol. 2018;19(12):67. https:\/\/doi.org\/10.1007\/s11864-018-0581-6.","journal-title":"Curr Treat Options in Oncol"},{"issue":"1","key":"613_CR72","first-page":"52","volume":"6","author":"C Aul","year":"1992","unstructured":"Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6(1):52\u20139.","journal-title":"Leukemia."},{"issue":"6","key":"613_CR73","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/cncr.23697","volume":"113","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351\u201361. https:\/\/doi.org\/10.1002\/cncr.23697.","journal-title":"Cancer."},{"issue":"6","key":"613_CR74","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079\u201388.","journal-title":"Blood."},{"issue":"12","key":"613_CR75","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365. https:\/\/doi.org\/10.1182\/blood-2012-03-420489.","journal-title":"Blood."},{"issue":"3","key":"613_CR76","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.v99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840\u20139. https:\/\/doi.org\/10.1182\/blood.v99.3.840.","journal-title":"Blood."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-021-00613-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00613-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T21:21:18Z","timestamp":1614806478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-021-00613-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":76,"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00613-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"4 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anthony Hunter has no relevant conflicts of interest. Eric Padron has received research funding from BMS, Kura, and Incyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}